Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | P-CD19CD20-ALLO1 |
| Synonyms | |
| Therapy Description |
P-CD19CD20-ALLO1 are allogeneic T stem cell-rich T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20, which potentially induces antitumor activity against CD19 and CD20-expressing tumor cells (Blood (2024) 144 (Supplement 1): 4805). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| P-CD19CD20-ALLO1 | P-CD19CD20-ALLO-1|P-CD19CD20-ALLO 1 | CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 | P-CD19CD20-ALLO1 are allogeneic T stem cell-rich T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20, which potentially induces antitumor activity against CD19 and CD20-expressing tumor cells (Blood (2024) 144 (Supplement 1): 4805). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |